Comment by epcoa
5 months ago
> as a sibling commenter writes, well-studied cases of this are so rare that
And yet not a single cite in sight. A random commenter on orange site is not evidence
However I know the paper they are referring to - it is from 1999 in J Pathology, famous at the time, and it is woefully out of date.
> they’re below our sensitivity of detection/technical error rates.
Hogwash.
https://www.mdpi.com/2076-0817/14/7/668
> There are ways to do this, and, should they be attained, would be published in a reputable journal based on their novelty.
There are plenty of papers on HPV independent cervical cancer based on actual gene expression methods published in reputable journals in the last 30 years.
> > as a sibling commenter writes, well-studied cases of this are so rare that
> And yet not a single cite in sight. A random commenter on orange site is not evidence
At a certain point, one has to take on the obligation of self-education.
> Hogwash.
From the website link you pasted: "Test-Specific Technical Issues - Standard tests (such as PCR or in situ hybridization) may not detect HPV types not included in the test panel (rare or classic non-oncogenic variants)."
> There are plenty of papers on HPV independent cervical cancer based on actual gene expression methods published in reputable journals in the last 30 years.
You don't understand the field, so you don't know why the gene expression does not establish the presence or absence of HPV but instead can be used as an argument for the absence of HPV.
EDIT: Also, a fundamental point of misunderstanding - cervical cancer is not a 'new' disorder, so unless you have an explanation for why the 1999 article is wrong, we can't simply discard its result and favor a next-generation sequencing article.
Well to bring this back to the original question: "What are these other ways?", how does GCA not qualify?